PPARs and other nuclear receptors in inflammation

Current Opinion in Pharmacology

Volumn 6, Issue 4, 2006, Pages 421-427

  Rizzo, Giovanni ^a   Fiorucci, Stefano ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIINFLAMMATORY AGENT; CELL NUCLEUS RECEPTOR; CIGLITAZONE; CORTICOSTEROID; DEXAMETHASONE; ENGLITAZONE; FARNESOID X RECEPTOR; FARNESOID X RECEPTOR LIGAND; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR AGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; STEROID; TROGLITAZONE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; COLITIS; CONTACT DERMATITIS; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENETIC CODE; HOMEOSTASIS; HUMAN; IMMUNOREGULATION; INFLAMMATORY DISEASE; INSULIN RESISTANCE; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; ATHEROSCLEROSIS; DNA-BINDING PROTEINS; HUMANS; INFLAMMATION; LIGANDS; ORPHAN NUCLEAR RECEPTORS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PPAR ALPHA; PPAR GAMMA; PPAR-BETA; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, GLUCOCORTICOID; TRANSCRIPTION FACTORS;

EID: 33745714392     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.03.012     Document Type: Review

References (56)

1. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., and Evans R.M. The nuclear receptor superfamily: the second decade. Cell 83 (1995) 835-839
2. Chawla A., Repa J., Evans R., and Mangelsdorf D. Nuclear receptors and lipid physiology: opening the X-files. Science 294 (2001) 1866-1870
3. Francis G.A., Fayard E., Picard F., and Auwerx J. Nuclear receptors and the control of metabolism. Annu Rev Physiol 65 (2003) 261-311
4. McKenna N.J., Lanz R.B., and O'Malley B.W. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20 (1999) 321-344
5. Rosenfeld M.G., and Glass C.K. Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem 276 (2001) 36865-36868
6. McKenna N.J., and O'Malley B.W. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108 (2002) 465-474
7. Glass C.K., and Rosenfeld M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14 (2000) 121-141
8. Reichardt H.M., Tuckermann J.P., Gottlicher M., Vujic M., Weih F., Angel P., Herrlich P., and Schutz G. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J 20 (2001) 7168-7173
9. De Bosscher K., Vanden Berghe W., and Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 24 (2003) 488-522
10. Ray A., and Prefontaine K.E. Physical association and function antagonism between the p65 subunit of transcription factor NF-κB and the glucocorticoid receptor. Proc Natl Acad Sci USA 91 (1994) 752-756
11. Garside R., Stein K., Wyatt K., Round A., and Pitt M. A cost-utility analysis of microwave and thermal balloon endometrial ablation techniques for the treatment of heavy menstrual bleeding. BJOG 111 (2004) 1103-1114
12. Liden J., Franck D., Rafter I., Guftafson J.Å., and Okret S. A new function for the C-terminal zinc finger of the glucocorticoid receptor; regression of RelA transactivation. J Biol Chem 272 (1997) 21467-21472
13. Ogawa S., Lozach J., Benner C., Pascual G., Tangirala R.J.K., Westin S., Hoffmann A., Subramaniam S., David M., Rosenfeld M.G., and Glass C.K. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 122 (2005) 707-721. A detailed analysis of the mode of action of glucocorticoids, as well as PPAR-γ and LXR, on immune activation induced by Toll receptor-4 engagement. This study provides evidence that interferon-responsive element and NF-κB interact with the NCoR to modulate gene transcription.
14. Ito K., Barnes P.J., and Adcock I.M. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 20 (2000) 6891-6903
15. Nagpal S., Lu J., and Boehm M.F. Vitamin D analogs: mechanism of action and therapeutic applications. Curr Med Chem 8 (2001) 1661-1679
16. Jiang C., Ting A.T., and Seed B. PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
17. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
18. Castrillo A., and Tontonoz P. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu Rev Cell Dev Biol 20 (2004) 455-480. A summary of recent studies on PPAR and LXR function in macrophage biology.
19. Kliewer S.A., Sundseth S.S., Jones S.A., Brown P.J., Wisely G.B., Koble C.S., Devchand P., Wahli W., Willson T.M., Lenhard J.M., and Lehmann J.M. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 94 (1997) 4318-4323
20. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., and Milburn M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395 (1998) 137-143
21. Horlein A.J., Naar A.M., Heinzel T., Torchia J., Gloss B., Kurokawa R., Ryan A., Kamei Y., Soderstrom M., Glass C.K., et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377 (1995) 397-404
22. Xu L., Glass C.K., and Rosenfeld M.G. Coactivator and corepressor complexes in nuclear receptor function. Curr Opin Genet Dev 9 (1999) 140-147
23. Chawla A., Lee C.H., Barak Y., He W., Rosenfeld J., Liao D., Han J., Kang H., and Evans R.M. PPARdelta is a very lowdensity lipoprotein sensor in macrophages. Proc Natl Acad Sci USA 100 (2003) 1268-1273
24. Ziouzenkova O., Perrey S., Asatryan L., Hwang J., MacNaul K.L., Moller D.E., Rader D.J., Sevanian A., Zechner R., Hoefler G., and Plutzky J. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci USA 100 (2003) 2730-2735
25. Braissant O., Foufelle F., Scotto C., Dauca M., and Wahli W. Differential expression of peroxisome proliferator-activated receptor (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137 (1996) 354-366
26. Inoue I., Shino K., Noji S., Awata T., and Katayama S. Expression of peroxisome proliferator-activated receptor alpha (PPAR-α) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 246 (1998) 370-374
27. Chinetti G., Griglio S., Antonucci M., Torra I.P., Delerive P., Majd Z., Fruchart J.C., Chapman J., Najib J., and Staels B. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 273 (1998) 25573-25580
28. Chinetti G., Lestavel S., Bocher V., Remaley A.T., Neve B., Torra I.P., Teissier E., Minnich A., Jaye M., Duverger N., et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7 (2001) 53-58
29. Marx N., Sukhova G.K., Collins T., Libby P., and Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99 (1999) 3125-3131
30. Goya K., Sumitani S., Xu X., Kitamura T., Yamamoto H., Kurebayashi S., Saito H., Kouhara H., Kasayama S., and Kawase I. Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol 24 (2004) 658-663
31. Marx N., Mackman N., Schonbeck U., Yilmaz N., Hombach V., Libby P., and Plutzky J. PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation 103 (2001) 213-219
32. Shu H., Wong B., Zhou G., Li Y., Berger J., Woods J.W., Wright S.D., and Cai T.Q. Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cell. Biochem Biophys Res Commun 267 (2000) 345-349
33. Vosper H., Patel L., Graham T.L., Khoudoli G.A., Hill A., Macphee C.H., Pinto I., Smith S.A., Suckling K.E., Wolf C.R., and Palmer C.N. The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages. J Biol Chem 276 (2001) 44258-44265
34. Fajas L., Auboeuf D., Raspe E., Schoonjans K., Lefebvre A.M., Saladin R., Najib J., Laville M., Fruchart J.C., Deeb S., et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 272 (1997) 18779-18789
35. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., and Evans R.M. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93 (1998) 241-252
36. Pasceri V., Wu H.D., Willerson J.T., and Yeh E.T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator activated receptor-gamma activators. Circulation 101 (2000) 235-238
37. Wakino S., Law R.E., and Hsueh W.A. Vascular protective effects by activation of nuclear receptor PPARgamma. J Diabetes Complications 16 (2002) 46-49
38. Takeda K., Ichiki T., Tokunou T., Funakoshi Y., Iino N., Hirano K., Kanaide H., and Takeshita A. Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 102 (2000) 1834-1839
39. Akiyama T.E., Sakai S., Lambert G., Nicol C.J., Matsusue K., Pimprale S., Lee Y.H., Ricote M., Glass C.K., Brewer Jr. H.B., and Gonzalez F.J. Conditional disruption of the peroxisome proliferatoractivated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol 22 (2002) 2607-2619
40. Thieringer R., Fenyk-Melody J.E., Le Grand C.B., Shelton B.A., Detmers P.A., Somers E.P., Carbin L., Moller D.E., Wright S.D., and Berger J. Activation of peroxisome proliferator activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo. J Immunol 164 (2000) 1046-1054
41. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., and Evans R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7 (2001) 48-52
42. Kelly D., Campbell J.I., King T.P., Grant G., Jansson E.A., Coutts A.G., Pettersson S., and Conway S. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 5 (2004) 104-112
43. Lee C.H., Chawla A., Urbiztondo N., Liao D., Boisvert W.A., Evans R.M., and Curtiss L.K. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302 (2003) 453-457
44. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., Fruchart J.C., Tedgui A., Haegeman G., and Staels B. Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kB and AP-1. J Biol Chem 274 (1999) 32048-32054
45. Pascual G., Fong A.L., Ogawa S., Gamliel A., Li A.C., Perissi V., Rose D.W., Willson T.M., Rosenfeld M.G., and Glass C.K. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437 (2005) 759-763. Sumoylation of PPARγ explains the inhibition of NF-κB by PPARγ ligands.
46. Soderstrom M., Wigren J., Surapureddi S., Glass C.K., and Hammarstrom S. Novel prostaglandin D(2)-derived activators of peroxisome proliferator-activated receptor-gamma are formed in macrophage cell cultures. Biochim Biophys Acta 1631 (2003) 35-41
47. Yang X.Y., Wang L.H., Mihalic K., Xiao W., Chen T., Li P., Wahl L.M., and Farrar W.L. Interleukin (IL)-4 indirectly suppresses IL-2 production by human T lymphocytes via peroxisome proliferator-activated receptor gamma activated by macrophage-derived 12/15-lipoxygenase ligands. J Biol Chem 277 (2002) 3973-3978
48. Wilson T.M., Cobb J.E., Cowan D.J., Wiethe R.W., Correa I.D., Prakash S.R., Beck K.D., Moore L.B., Kliewer S.A., and Lehmann J.M. The structure activity relationship between peroxisome proliferator-activated receptor-γ agonism, and anti-hyperglycaemic activity of thiazolidinediones. J Med Chem 39 (1996) 665-668
49. Lusis A.J. Atherosclerosis. Nature 407 (2000) 233-241
50. Joseph S.B., Castrillo A., Laffitte B.A., Mangelsdorf D.J., and Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 9 (2003) 213-219
51. Castrillo A., Joseph S.B., Marathe C., Mangelsdorf D.J., and Tontonoz P. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J Biol Chem 278 (2003) 10443-10449
52. Terasaka N., Hiroshima A., Ariga A., Honzumi S., Koieyama T., Inaba T., and Fujiwara T. Liver X receptor agonists inhibit tissue factor expression in macrophages. FEBS J. 272 (2005) 1546-1556
53. Fowler A.J., Sheu M.Y., Schmuth M., Kao J., Fluhr J.W., Rhein L., Collins J.L., Willson T.M., Mangelsdorf D.J., Elias P.M., and Feingold K.R. Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production. J Invest Dermatol 120 (2003) 246-255
54. Fiorucci S., Antonelli E., Rizzo G., Renga B., Mencarelli A., Riccardi L., Orlandi S., Pellicciari R., and Morelli A. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127 (2004) 1497-1512
55. Fiorucci S., Rizzo G., Antonelli E., Renga B., Mencarelli A., Riccardi L., Antonio M., Pruzanski M., and Pelllicciari R. Crosstalk between farnesoid X-receptor (FXR) and peroxisome proliferator-activated receptor (PPAR){gamma} contributes to the anti-fibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther 315 (2005) 58-68. A paper describing the effect of FXR activation on AP-1 components. FXR activation leads to small heterodimer protein-dependent inhibition of AP-1 binding to target genes.
56. Fiorucci S., Rizzo G., Antonelli E., Renga B., Mencarelli A., Riccardi L., Orlandi S., Pruzanski M., Morelli A., and Pellicciari R. A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther 314 (2005) 584-595